Navigation Links
Regenerative Medicine and Stem Cells Market Deals Analysis in New Research Report at ReportsnReports.com
Date:2/12/2013

sp;What sublicensing and subcontracting provisions have been agreed?
  •     Which boilerplate clauses does the company insist upon?
  •     Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  •     Which jurisdiction does the company insist upon for agreement law?
  • The initial chapters of this report provide an orientation of drug deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in regenerative medicine and stem cells deal making since 2009, including details of average headline, upfront, milestone and royalty terms.

    Chapter 3 provides a review of the leading regenerative medicine and stem cells deals since 2009. Deals are listed by headline value, signed by big pharma, most active big pharma, and most active of all bio pharma companies.

    Chapter 4 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of regenerative medicine and stem cells deals, as well as contract documents available in the public domain.

    Chapter 5 provides a comprehensive and detailed review of regenerative medicine and stem cells partnering deals signed and announced since 2009, where a contract document is available in the public domain.

    In addition, a comprehensive appendix is provided organized by regenerative medicine and stem cells partnering company A-Z, deal type definitions and regenerative medicine and stem cells partnering agreements example. Each deal title links via Web link to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

    In conclusion, thi
    '/>"/>

    Source: PRWeb
    Copyright©2012 Vocus, Inc.
    All rights reserved

    Page: 1 2 3 4

    Related biology technology :

    1. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
    2. The Alliance for Regenerative Medicine forms Tissue Engineering and Biomaterials Committee
    3. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
    4. IntelliCell BioSciences Announces It Will Present and Run Workshop at the 10th Annual Commercialization of Regenerative Medicine in London
    5. Neuralstem CEO to Present at the World Stem Cells and Regenerative Medicine Congress in London
    6. Regenerative Sciences Receives $2M Investment for Orthopedic Stem Cell Initiatives
    7. ODT Forum Presents Regenerative Technologies
    8. Palm Beach Residents to Learn How the Future of Regenerative Medicine Will Combat Aging
    9. EastBridge Investment Group Announces Completion of its Merger with Cellular Biomedicine Group - Shareholder Conference Call to be held February 8th
    10. ALCAT Pioneer, Roger Deutsch, to Address "Food Allergies and Intolerances" at the Institute of Functional Medicine Conference in Tampa, February 8-10
    11. Southwest Integrative Medicine Offers Free eBook "Do Your Hormones Need Balancing?"
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/22/2014)... /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... its Oral Amphotericin B program.  The company recently ... work involving samples from HIV/AIDS patients exposed ... pre clinical studies and regulatory filings to move ... utilizing approximately $700,000 of funding and technological advice ...
    (Date:10/20/2014)... Oct. 20, 2014 Mapp Biopharmaceutical,s valiant ... antibody therapeutic to fight the Ebola outbreak will ... time-consuming the production of pharmaceuticals can be, according ... said that while some may be taken aback ... those with industry knowledge are well aware of ...
    (Date:10/20/2014)... -- GenVec, Inc. (NASDAQ: GNVC ) today announced the ... board of directors effective on October 24, 2014.   Dr. Horovitz ... its chairman from June 2006 to November 2013.  During his ... and Audit Committees of the board.  "We ... service to GenVec, and its stockholders," said Wayne T. ...
    (Date:10/19/2014)... The Latin American hardware encryption display market ... with analysis and forecast of revenue. This market was ... to reach $2,366.8 million by 2018, at a CAGR ... the TOC of the Latin American hardware encryption market ... provided. It also provides a glimpse of the segmentation ...
    Breaking Biology Technology:iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Zola P. Horovitz To Retire From GenVec Board 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3
    ... 3SBio Inc. (Nasdaq:,SSRX), a leading China-based biotechnology company ... today,announced the results of the shareholder votes at ... September 12, 2008 (Friday) at 10:00 a.m.,(Beijing time)., ... Dr. Jing Lou,Liping Xu, Bin Huang, Lawrence S. ...
    ... in Routine Vaccination Program ... -, COLLEGEVILLE, Pa., Sept. 15 Wyeth,Pharmaceuticals, ... today announced that,South Africa has initiated an immunization ... Vaccine,Adsorbed), a vaccine which helps protect infants and ...
    ... Bulletin Board: CBPC) announced today that it has filed ... an amendment to its Certificate,of Incorporation to effect a ... ("Common Stock") will begin trading on a,reverse-split basis on ... By unanimous written consent dated July 3, 2008 the ...
    Cached Biology Technology:South Africa Begins Introduction of PREVENAR into Childhood Immunization Program 2South Africa Begins Introduction of PREVENAR into Childhood Immunization Program 3South Africa Begins Introduction of PREVENAR into Childhood Immunization Program 4China Biopharma Effects 1 for 100 Reverse Stock Split 2China Biopharma Effects 1 for 100 Reverse Stock Split 3
    (Date:10/22/2014)... , Oct. 20, 2014  Leading identity analyst ... time half of the world,s population will have a ... Europe . Asia ... the market accounting for more than 60% of all ... Acuity,s report  -- "The Global National eID ...
    (Date:10/18/2014)... with undiagnosed, suspected genetic conditions, a certain type of ... diagnostic yield than traditional molecular diagnostic methods, according to ... is being released to coincide with the American Society ... sequences the protein­coding region of the genome (the complete ... cell or organism), has been rapidly applied in research ...
    (Date:10/16/2014)... war on the human body. Battles are won, ... pancreatic cancer, this stalemate—known as tumor dormancy—can last ... a phenomena that is poorly understood. , ... of Salvatore Torquato, a Professor of Chemistry at ... tumor dormancy and the switch to a malignant ...
    Breaking Biology News(10 mins):Half the World's Population Will Have Chip-Based National Electronic Identity (eID) Cards by 2018 2Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Modeling tumor dormancy 2
    ... wetlands are vital to the water cycle and ... GlobWetland, an ESA-led initiative in collaboration with the ... by using satellite imagery to provide detailed wide-area ... local conservation efforts. , Because the success of ...
    ... bacterial surface proteins that generate the strongest immune ... Chicago have created a vaccine that significantly protects ... Staphylococcus aureus, the most common cause of hospital-acquired ... illness. , The vaccine protected mice against ...
    ... an experimental targeted therapy with a common anti-inflammatory ... cancer, researchers at UCLA's Jonsson Cancer Center reported. ... anti-inflammatory drug Celebrex increased response rates in lung ... Reckamp, an assistant professor of hematology/oncology and lead ...
    Cached Biology News:African wetland managers armed with new technology 2MRSA vaccine shows promise in mouse study 2MRSA vaccine shows promise in mouse study 3Combination therapy shows promising results in patients with advanced lung cancer 2Combination therapy shows promising results in patients with advanced lung cancer 3
    ...
    ... is the first fully genetically encoded fluorescent ... intracellular hydrogen peroxide (H2O2), one of the ... the basis of yellow fluorescent protein inserted ... protein OxyR (OxyR-RD), HyPer demonstrates submicromolar affinity ...
    Alexa Fluor 647 anti-mouse Qa-2...
    ... essential for hunting and analyzing the ... as EST sequencing projects, microarrays, functional ... is developed for normalization of cDNA ... for directional cloning. While most normalization ...
    Biology Products: